Nutrition-based approach to support antigen-specific immunotherapy in subjects with cow's milk or peanut allergy

Nutrition-based approach to support antigen-specific immunotherapy in subjects with cow's milk or peanut allergy - Nutrition-based approach for antigenspecific immunotherapy for food allergy

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON43691

Enrollment

Registered

2016-09-15

Start date

2016-02-08

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Food Allergy

Interventions

Food Allergy

Fructo-oligosaccharides

Galacto-oligosachharides

Immunotherapy

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: Patients with established cow*s milk or peanut allergy (determined by food provocation) in the age of 18-65 years from our outpatient clinic Allergology/Dermatology

Exclusion criteria

Exclusion criteria: Pregnancy and use of systemic immunosuppressants (the continuous use, not local usage as an effect of an allergic reaction, e.g. prednison)

Design outcomes

Primary

Measure	Time frame
The T-cell response (measured by cytokine production) and phenotype of these cells (Th1/Th2/Treg by flow cytometry) in patients before and after stimulation of their isolated cells from blood with specific allergen (whey or peanut) and the influence and effect of NDOs on this response (with/without presence of artificial CpG DNA or Bifidobacterium breve DNA)	—

Secondary

Measure	Time frame
Changes in cytokine and chemokine profile of PBMCs after stimulation with NDOs will be studied. Also changes in cytokine and proliferation within subpopulations of the PBMCs will be studied (e.g. Dendritic cells or T-cells) and the interaction between these groups. To study safety of the NDOs, the activation of basophils will also be monitored.	—

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)